Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | BCL2 | P10415 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30425848 | 0.72 | SMN1; SMN2 (0.48) | CA12CA1CA2CA9CA14 | |
| SCHEMBL1263770 | 0.72 | SMN1; SMN2 (0.48) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL636847 | 0.72 | SMN1; SMN2 (0.48) | CA12CA1CA2CA9CA14 | |
| Bromide SCHEMBL637005 | 0.70 | SMN1; SMN2 (0.47) | CA12CA1CA2CA9CA14 | |
| SCHEMBL26186710 | 0.68 | CA12 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL7262939 | 0.66 | CA12 (0.37) | CA12CA1CA2CA9CA14 | |
| SCHEMBL26806792 | 0.65 | CA12 (0.46) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL6919283 | 0.62 | CA12 (0.38) | CA12CA1CA2CA9CA14 | |
| Hydrochloric Acid SCHEMBL31750726 | 0.62 | CA12 (0.38) | CA12CA1CA2CA9CA14 | |
| SCHEMBL29913142 | 0.62 | CA12 (0.48) | CA12CA1CA2CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | USHER III INITIATIVE, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149399-A1 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | TNF, HLA-DRB1, GSTK1 | CA12 511/4885CA1 2195/4885CA2 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.